Collectively, our study revealed that the C1RL-AS1/AKT/GSK3β/β-catenin/c-Myc pathway promotes a malignant phenotype in GC, indicating that it might be an attractive therapeutic target for GC patients in the future. The gene discussed is AKT1; the disease is gastric cancer.